Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000734213 | SCV000862337 | uncertain significance | not provided | 2018-07-09 | criteria provided, single submitter | clinical testing | |
Rolfs Rare Disease Consulting, |
RCV003485639 | SCV004232518 | likely pathogenic | Progressive familial intrahepatic cholestasis type 2 | 2021-01-01 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV004569420 | SCV005059074 | likely pathogenic | Benign recurrent intrahepatic cholestasis type 2 | 2024-03-30 | criteria provided, single submitter | clinical testing | |
Broad Center for Mendelian Genomics, |
RCV003485639 | SCV005907421 | uncertain significance | Progressive familial intrahepatic cholestasis type 2 | 2025-01-22 | criteria provided, single submitter | curation | The p.Arg1226Cys variant in ABCB11 has been reported in 2 individuals with BSEP deficiency (PMID: 35894240, vanWessel et al. 2020), and has been identified in 0.01% (7/59980) of Admixed American chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs772241929). Although this variant has been seen in the general population in a heterozygous state, its frequency is not high enough to rule out a pathogenic role. This variant has also been reported in ClinVar (Variation ID: 597949) and has been interpreted as likely pathogenic by Rolfs Rare Disease Consulting (Rolfs Consulting Und Verwaltungs GmbH) and Baylor Genetics, and as a variant of uncertain significance by Eurofins Ntd Llc (ga). Of the two affected individuals, one of those was a homozygote, which increases the likelihood that the p.Arg1226Cys variant is pathogenic (vanWessel et al. 2020). In summary, the clinical significance of the p.Arg1226Cys variant is uncertain. ACMG/AMP Criteria applied: PP3_moderate, PM2_supporting, PM3_supporting (Richards 2015). |